Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis
Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...
Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP
Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma
Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management
Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
Risk of Thrombosis in Patients With Cancer and Implanted Ports
Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...
Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia
Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia
Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...
Insurance Status Contributes to Survival Disparities in Follicular Lymphoma
Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...
No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome
Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML
Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
